InMode's (INMD) Hold Rating Reiterated at Needham & Company LLC

Needham & Company LLC reaffirmed their hold rating on shares of InMode (NASDAQ:INMD - Free Report) in a report released on Monday morning,Benzinga reports.

Other research analysts have also issued reports about the stock. Barclays upped their target price on shares of InMode from $26.00 to $29.00 and gave the company an "overweight" rating in a report on Wednesday, February 5th. Jefferies Financial Group decreased their target price on shares of InMode from $16.00 to $15.00 and set a "hold" rating on the stock in a research report on Monday, April 14th. Seven research analysts have rated the stock with a hold rating and one has given a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $18.54.

InMode Price Performance

INMD traded down $0.13 during midday trading on Monday, reaching $14.57. 1,081,285 shares of the company's stock were exchanged, compared to its average volume of 1,191,949. The business's 50-day moving average price is $16.89 and its 200 day moving average price is $17.56. The stock has a market capitalization of $1.01 billion, a PE ratio of 6.20 and a beta of 1.96. InMode has a 1-year low of $13.68 and a 1-year high of $19.85.

InMode (NASDAQ:INMD - Get Free Report) last posted its earnings results on Monday, April 28th. The healthcare company reported $0.31 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.45 by ($0.14). The company had revenue of $77.87 million during the quarter, compared to analysts' expectations of $82.21 million. InMode had a net margin of 45.91% and a return on equity of 18.25%. InMode's quarterly revenue was down 3.0% compared to the same quarter last year. During the same period in the previous year, the company posted $0.32 EPS. As a group, analysts expect that InMode will post 1.75 EPS for the current fiscal year.

Institutional Trading of InMode

A number of institutional investors and hedge funds have recently made changes to their positions in the company. CWM LLC increased its position in InMode by 106.4% during the 1st quarter. CWM LLC now owns 2,369 shares of the healthcare company's stock worth $42,000 after purchasing an additional 1,221 shares in the last quarter. Orion Capital Management LLC purchased a new stake in InMode during the 4th quarter worth $65,000. SBI Securities Co. Ltd. acquired a new stake in InMode in the 4th quarter valued at $87,000. Farther Finance Advisors LLC raised its holdings in shares of InMode by 26.2% during the 4th quarter. Farther Finance Advisors LLC now owns 5,555 shares of the healthcare company's stock valued at $93,000 after buying an additional 1,154 shares during the period. Finally, Covestor Ltd lifted its position in InMode by 13.9% during the 4th quarter. Covestor Ltd now owns 5,936 shares of the healthcare company's stock worth $99,000 after acquiring an additional 723 shares in the last quarter. 68.04% of the stock is currently owned by institutional investors and hedge funds.

InMode Company Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.